legacy12159_breast_cancer

Breast cancer cohort from the Phase 1b trial (NCT01623349). Eligible patients had recurrent triple-negative breast cancer (TNBC), or recurrent breast cancer of any subtype with a germline BRCA mutation and were enrolled to a dose escalation or expansion cohort.本数据集源自编号为NCT01623349的1b期临床试验的乳腺癌队列。符合入组标准的患者为复发性三阴性乳腺癌（triple-negative breast cancer, TNBC）患者，或携带生殖系BRCA突变的任意亚型复发性乳腺癌患者，且被纳入剂量爬坡队列或扩展队列。